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Case Report
Introduction
Stromal tumors are the prominent mesenchymal tumors of gastrointestinal tract (GIT) (1). They are more apparent in upper mid-
dle age, mostly in 5th and 6th decades. They occur equally in both sexes (1). Gastrointestinal Stromal Tumors (GISTs) are most com-
monly localized in the stomach (40-70%) and may be found in the intestine (20-32%), colon (10%) and esophagus (5%) (1, 2). 
They also can be seen in extra-GIT sites like mesentery, omentum and retroperitoneum (2). Major patient complaints regarding 
GISTs are upper abdominal pain, GIT bleeding and abdominal masses (1). Interstitial cells of Cajal (ICC), which GISTs are thought 
to originate from, both express tyrosine kinase receptors (c-kit) and stain with CD34 and Vimentin. KIT (CD117) is a transmem-
brane tyrosine kinase receptor, which is expressed in hematopoietic stem cells, germ cells, mast cells, melanocytes and ICC (2). 
 C-Kit positivity is an important parameter in diagnosis of GIST. Recently, a specific marker, namely discovered on GIST1 (DOG-1), has been 
discovered for GIST diagnosis. It is shown to be positive on ICCs and gastric surface epithelium. DOG-1 is also expressed in high amounts in 
KIT mutation-negative cases besides typical GIST cases (3). Immunohistochemical diagnosis of GIST is adopted when mesenchymal 
tumors stain positive with c-Kit (CD117) and the DOG-1 where the rest of mesenchymal cell markers were negative. Demonstration of 
CD117 and recently DOG-1 positivity immunochemically stands for the standard technique of definitive diagnosis of GIST. CD34 is 
positive in 70-80% of the cases. Vimentin is diffuse and strong positive in many stromal tumors. SMA is positive in 30-40% and S100 in 
5% of GISTs. Staining with desmin is rare (1). Malignant stromal tumors mostly metastasize to liver, peritoneum, lungs and bones (4). 
Brain and lymph node metastases are unusual (4). No breast metastasis was presented in literature before.
Hereby, we present a case of GIST with liver, bone, lymph node and breast metastases and aimed to discuss its unusual metastatic review-
ing literature. 
Case Presentation
A 46 year-old woman was referred to us from another health facility with the complaint of back pain. The radiological imaging studies 
revealed multiple liver metastases with the largest being 5.5 cm in diameter as well as multiple bone involvements. Positron Emission 
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Computed Tomography (PET-CT, General Electric Medical System, 
Milwaukee, USA) demonstrated elevated F-18-fluoro-2-deoxyglucose 
(FDG) uptake in her left breast in addition to the above-mentioned 
lesions. Histologic samples taken from abdominal lymph nodes and 
liver revealed neoplastic lesions composed of cells with prominent 
hyperchromatic nuclei and spindle-shaped cytoplasm. Immunohisto-
chemistry studies showed strong positive staining with CD117 (Code 
A4502, Dako, California) in Figure 1 and DOG-1 (Clone SP31, 
Thermo Scientific, USA) in Figure 2, positive staining with Vimen-
tin (Code-Nr. M 0725, Dako, Denmark) and negative staining with 
CD34 (Clone QBEnd-10, Dako, Denmark), S100 (Code ZO311, 
Dako, Denmark) and Desmin (Clone D33, Dako, Denmark) in both 
liver and lymph node tissues. The patient was diagnosed to have GIST 
metastasis and therefore was started on imatinib therapy. A control 
PET-CT obtained on the second month of imatinib treatment dem-
onstrated progression in liver metastases, variable response in bone me-
tastases and partial regression in breast and lymph node metastases. No 
mass was observed on the physical examination of either of the breasts 
and the axillae. Breast ultrasound and Magnetic Resonance Imaging 
showed two small lesions of 5 and 3 mm in close location, which both 
were thought to be benign.
 As for the fact that nuclear regression had been experienced in the left 
breast under imatinib therapy, tissue diagnosis was planned to rule out 
malignancy. After the suspected area was marked with needle localiza-
tion by ultrasound, a wide excisional biopsy was performed. When 
the specimen of 10x4x4 cm yellow color fatty tissue was examined 
macroscopically in serial sections, no significant mass was observed 
in cross-sectional surfaces. Complete sampling of the specimen dem-
onstrated fibroadipose and acinar tissue, as well as two lesions in 3x2 
mm and 2x2 mm size composed of spindle cells with prominent nuclei 
and spindle-shaped cytoplasm (Figure 3). These cells stained strongly 
with CD117 (Figure 4) and DOG1 (Figure 5) and did not stain with 
S100, CD34 and SMA (Clone 1A4, Code M0851, Dako, Denmark) 
immunohistochemically. Microscopy in 10x High Power Magnifica-
tion (HPM) of these lesions showed 4-5 mitoses. Ki67 (Clone MIB-1, 
Coce M7240, Dako, Denmark) proliferation index was calculated as 
3-4%. The case was interpreted as a GIST metastasizing to liver, lymph 
nodes, bones and breast when evaluated immunohistochemically with 
its histomorphological findings. 
A lumbar MRI scan was obtained due to increased bone pain, which 
revealed progressive bone metastases. The imatinib dose was doubled; 
however, she was lost to follow-up. Patient gave orally informed consent.
Discussion and Conclusion
Gastrointestinal stromal tumors (GISTs) can occur anywhere along 
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Figure 1. CD117 positivity by immunohistochemistry in liver 
Figure 2. DOG 1 negative in lymphoid cells in lymph node, while 
positive in infiltration areas
Figure 3. Tumor infiltration well separated from mammary stroma, 
as well as ductal structures 
(H&E stain, x100)
Figure 4. CD117-positive tumor areas in breast
the Gastrointestinal tract (GIT) from esophagus to anus besides in 
omentum, mesentery, retroperitoneum deriving from Interstitial cells 
of cajal (ICCs) (3, 5). C-kit and DOG-1 positivity in used in the 
pathologic diagnosis of GISTs (3). Stromal tumors like leiomyomas, 
leiomyosarcomas, desmoid tumors, mesenteric fibromatosis and fibro-
sarcomas are considered in differential diagnosis. Tumor size, number 
of mitosis and localization are the most important prognostic factors 
of GISTs (1). GISTs are structured as spindle-like in 70%, epitheli-
oid in 20% and mixed in 10%. Spacing signet-ring-like areas can also 
be observed. Major route of metastases of malignant stromal tumors 
are liver, peritoneum, lungs and bones (4). Brain and lymph node 
metastases are extraordinary (4). No breast metastasis of GIST was 
declared before. There are cases in the literature presenting invasive 
breast cancer of the breast accompanying GIST as a second primary 
tumor (6, 7). Subash et al. (6) presented a case with GIST in which 
Position Emission Computed Tomography (PET-CT) demonstrated 
an increased uptake in her left breast and breast biopsy proved an inva-
sive ductal breast cancer . Obinna et al. (4) presented a case with GIST 
who developed an intramammary lymph node metastasis and intesti-
nal metastasis . Our case presentation seems to be the first in literature 
to demonstrate a breast metastasis of GIST. CD117 is expressed in 
Phyllodes tumors (PT) of breast (8). This study showed weak staining 
with CD117 in 5 of 17 PTs (8). 
Gastrointestinal stromal tumors rarely can contain signet-ring-like 
components. Epithelioid type GISTs comprising signet-ring-like cells 
must be differentiated from invasive lobular cancers of breast in terms 
of diagnosis. In the study of Yared et al. (9) CD117 was applied to the 
tissue samples obtained from 21 normal breast epithelia, 24 benign 
breast lesions, 29 in situ breast carcinomas and 41 invasive carcino-
mas. Positive staining was demonstrated in 100% of normal breast 
epithelia, 88% of benign breast lesions, 20% of in situ carcinomas and 
18% of invasive breast carcinomas. Of the 6 invasive breast cancers 
which stained strong positive, two were lobular, one was ductal and 
one was signet ring cell cancers . Also, CD117 positivity was shown 
in a case of gastric epithelioid GIST presented in the literature, which 
later presented an axillary mass and ER and GCDFP- 15 positivity in 
breast and gastric samples resulting in the diagnosis of primary lobular 
carcinoma of the breast and a gastric metastasis (10). 
Therefore, especially before diagnosing epithelioid-type stromal tu-
mors, lobular and signet ring cell carcinomas of the breast must be dif-
ferentiated by immunohistochemical and radiological examinations. 
Studies concerning GIST in the literature commonly present liver, 
lung and bone metastases. Hereby, we presented the first case of GIST 
metastasizing to breast, which we think is a very extraordinary condi-
tion and discussed according to the literature. It must be kept in mind 
that demonstration of a spindle cell neoplasia can either belong to a 
primary tumor or a metastasis. Therefore, CD117, which is stained 
both in GIST and most spindle cell bearing conditions of the breast 
such as Phyllodes tumors, and DOG1 staining studies must be added 
to foresee GIST metastasis. 
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Figure 5. DOG1-positive tumor areas in breast
